Coenzyme Q10 (Ubiquinol) for ALS
Also known as: CoQ10, Ubiquinol, Ubiquinone
CoQ10 targets mitochondrial dysfunction — a central feature of ALS motor neuron degeneration.
Mechanism of Action
CoQ10 serves as an electron carrier between Complex I/II and Complex III of the mitochondrial electron transport chain. In its reduced form (ubiquinol), it's the most potent lipid-soluble antioxidant, neutralizing lipid peroxyl radicals and regenerating vitamin E. Motor neurons are particularly vulnerable to mitochondrial dysfunction due to their high energy demands.
General mechanism: Mitochondrial electron transport chain cofactor (Complex I/II → III). Lipid-soluble antioxidant. Regenerates vitamin E.
Current Evidence
Phase II ALS trial showed no significant benefit at tested doses (2400mg/day). Higher doses and combination strategies are being explored. The QALS study highlighted the importance of sufficient dosing and duration in neuroprotection trials.
Clinical Status: Phase II completed for ALS (negative at tested doses). Available as supplement. Higher-dose studies considered.
Safety Profile
Very safe. Mild GI effects. May interact with warfarin (vitamin K-like structure). Well-tolerated at high doses (2400mg+).
Key Research Questions
- Can higher CoQ10 doses or ubiquinol formulations achieve therapeutic CNS concentrations?
- Does combination with other mitochondrial support (NMN, TUDCA) provide synergistic benefit?
- Which ALS subtypes with prominent mitochondrial dysfunction might respond better?